Last reviewed · How we verify

etomidate, fentanyl, and lidocaine

Drexel University College of Medicine · FDA-approved active Small molecule

This is a combination of three agents that work together: etomidate provides rapid sedation via GABA-A receptor agonism, fentanyl provides analgesia via opioid receptor agonism, and lidocaine provides local anesthesia via sodium channel blockade.

This is a combination of three agents that work together: etomidate provides rapid sedation via GABA-A receptor agonism, fentanyl provides analgesia via opioid receptor agonism, and lidocaine provides local anesthesia via sodium channel blockade. Used for Rapid sequence intubation and induction of general anesthesia, Procedural sedation and analgesia.

At a glance

Generic nameetomidate, fentanyl, and lidocaine
SponsorDrexel University College of Medicine
Drug classAnesthetic combination (hypnotic + opioid + local anesthetic)
TargetGABA-A receptor (etomidate), mu opioid receptor (fentanyl), voltage-gated sodium channels (lidocaine)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Etomidate is a non-barbiturate hypnotic that enhances inhibitory GABA-A signaling in the central nervous system to induce unconsciousness. Fentanyl is a potent synthetic opioid agonist that binds mu opioid receptors to provide analgesia and sedation. Lidocaine is a local anesthetic that blocks voltage-gated sodium channels to prevent pain signal transmission. Together, these agents provide rapid sequence intubation anesthesia with analgesia and local pain control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results